Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 mg | $41 | In Stock | |
1 g | $48 | In Stock |
Description | Gatifloxacin (CG5501) is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. |
In vitro | Gatifloxacin increases serum adrenaline levels in both normal and diabetic rats, and concurrently reduces serum glucose concentrations in these subjects. |
In vivo | Gatifloxacin exhibits potent inhibitory activity against bacterial type II topoisomerases, with half-maximal inhibitory concentrations (IC50) of 13.8 mg/mL and 0.109 mg/mL for Staphylococcus aureus topoisomerase and Escherichia coli DNA gyrase, respectively. Its inhibitory effect on HeLa cell topoisomerase II is minimal, with an IC50 of 265 mg/mL. Gatifloxacin inhibits Mycobacterium tuberculosis ATCC 35801 with a minimum inhibitory concentration (MIC) of 0.125 μg/mL. When used in combination with ciprofloxacin, gatifloxacin demonstrates a synergistic effect on 19% of 31 strains of Pseudomonas aeruginosa. However, gatifloxacin's activity is two-fold lower than that of ciprofloxacin and two-fold less potent than ofloxacin against Enterobacteriaceae. Gatifloxacin shows strong antimicrobial activity against Haemophilus influenzae, Legionella, and Helicobacter pylori (MIC90s, 0.03-0.06 mg/L), and at least an eight-fold greater efficacy against Chlamydiaceae and Mycoplasmataceae (gatifloxacin MIC90s, 0.13 mg/L). |
Alias | BMS 206584-01, PD 135432, CG5501, BMS-206584, AM-1155 |
Molecular Weight | 375.39 |
Formula | C19H22FN3O4 |
Cas No. | 112811-59-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||
Solubility Information | DMSO: 3.8 mg/mL (10 mM) | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.